Exelixis is a rare biotech that scores strongly on all five axes at once. The Cabometyx (cabozantinib) franchise is a high-margin cash machine that funds one of the most aggressive buyback programs in the sector, while the next-generation TKI zanzalintinib — NDA accepted, PDUFA target December 3, 2026 — opens a multi-tumor expansion management frames as a $5B opportunity. Four consecutive earnings beats, a 16x forward PE with a ~0.5 PEG, 96% gross margins, and a genuinely clean balance sheet (no equity dilution, shares shrinking). The one caveat keeping this an A rather than A+: price sits just under its all-time high while the published analyst consensus target ($49) is below spot — the upside relies on a continued re-rating, not on consensus mean-reversion. A momentum + value combination that is hard to find at this size, but entered near a record high.StockAnalysis· live
Exelixis is a profitable, commercial-stage oncology company built around cabozantinib, marketed as Cabometyx (tablets) and Cometriq (capsules). Cabozantinib is a tyrosine kinase inhibitor (TKI) approved across renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer, and — following the 2025 STELLAR-303 program build-out — neuroendocrine tumors. It is the company's engine: net product revenue of roughly $2.12B in FY2025, up about 17% year over year, at a 96% gross margin.Exelixis IR· fév 2026
The growth story is zanzalintinib — a next-generation oral TKI designed to improve on cabozantinib's profile. Its lead indication is previously treated metastatic colorectal cancer (combined with atezolizumab); the FDA accepted the NDA with a PDUFA target action date of December 3, 2026, backed by phase 3 STELLAR-303 overall-survival data. Management describes a broadened program of seven pivotal studies across GU and GI cancers and frames the total opportunity at roughly $5 billion. The thesis is simple: a high-margin cash machine funds aggressive capital return today, while a credible multi-tumor pipeline supplies the next leg of growth — at a valuation that prices in almost none of it.Yahoo Finance· 2026
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $2.38B | +10% YoY |
| Net Product Revenue (FY25) | $2.12B | +17% YoY |
| Net Income (TTM) | $833M | Profitable |
| EPS (TTM) | $3.02 | Growing |
| Gross Margin | ~96% | Best-in-class |
| Operating Margin | ~37% | Strong |
| Cash & Equivalents | ~$0.98B | Net cash |
| Total Debt | Minimal | D/E ~8% |
| P/E (Trailing) | 17.6x | Reasonable |
| Fwd P/E | 16.1x | Cheap for growth |
| PEG | ~0.5 | Value |
| Analyst Target (consensus) | $49 | Recent: $48–$55 |
Note on the target: the published consensus average ($46–$49) lags a sharp re-rating — TD Cowen lifted to $55, H.C. Wainwright to $52, Citizens to $50 in 2026 as zanzalintinib de-risked. Spot already sits at/above the stale consensus, which is why the trade is framed as momentum-with-fundamental-support rather than deep-discount mean reversion.StockAnalysis Forecast· 2026
This is where EXEL separates itself from most of the sector. There is no dilution risk — quite the opposite. There has been no S-3 equity raise, no ATM program, and no 424B5 prospectus for new shares; the share count is shrinking.SEC EDGAR (CIK 0000939767)· 2026
Dilution is not merely absent — it is negative. With shares being retired faster than equity-based comp is issued and a fresh $750M program in flight, EXEL's per-share economics are mechanically improving regardless of price action.
| Price | $53.13 |
| RSI (14) | 61.8 |
| EMA 20 | $51.06 |
| EMA 50 | $48.56 |
| EMA 200 | $44.47 |
| ATR (14) | $1.51 |
| 52W Range | $33.76 – $53.93 |
Textbook bullish structure. Price ($53.13) sits just below the 52-week / all-time high of $53.93 after a methodical markup off the $33.76 low. The moving-average stack is perfectly ordered — EMA20 ($51.06) > EMA50 ($48.56) > EMA200 ($44.47) — with healthy separation. RSI at 61.8 is firmly in momentum territory but not stretched, and price is only ~4.1% above the EMA20, so the move is not over-extended. ATR of $1.51 (~3% of price) makes for clean, mechanical risk sizing. The setup is a classic ATH coil: a small pullback into the rising EMA20 offers the highest-quality entry, with a breakout above $53.93 confirming continuation.Finviz· live
A profitable, net-cash large-cap with no dilution and best-in-class margins keeps the structural risk low. The two live risks are franchise concentration (one molecule does most of the work) and binary pipeline read-throughs from the H2 2026 zanzalintinib catalysts.
The biggest fears in biotech — cash burn, dilution, going-concern doubt — simply do not apply here. EXEL is profitable, generates real free cash flow, holds net cash, and is buying back stock. That removes most of the tail risk. What remains is the normal pharma profile: one franchise carries the P&L, and a binary pipeline catalyst can swing sentiment in H2 2026. Those are real but well-telegraphed, and the base business stands on its own even in a disappointing pipeline scenario.
Buy the ATH coil with a fundamental floor. The Cabometyx cash machine funds an aggressive, ongoing buyback ($750M fresh authorization) while zanzalintinib — NDA accepted, PDUFA Dec 3 2026, STELLAR-303 OS-positive — opens a multi-tumor expansion at a ~0.5 PEG. The buy-limit at $52.68 sits just below spot, into the rising structure; the stop at $50.11 is parked below the EMA20 at ~1.7 ATR. TP1 ($57.82) is a measured-move breakout target above the $53.93 high; TP2 ($60.90) is the catalyst-driven stretch into the H2 2026 readouts. Both targets clear the 1.5 R/R minimum (2.0 and 3.2). With beta 0.44 and a continuous buyback bid, the downside is comparatively well-defended for a momentum entry.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data sourced from Yahoo Finance, StockAnalysis.com, SEC EDGAR, and Exelixis investor relations. Accuracy is not guaranteed.